{
    "root": "31578bff-5dbb-ec62-e063-6294a90a36a5",
    "code": "34391-3",
    "codeSystem": "2.16.840.1.113883.6.1",
    "displayName": "HUMAN PRESCRIPTION DRUG LABEL",
    "name": "NALTREXONE HYDROCHLORIDE",
    "value": "20250327",
    "ingredients": [
        {
            "name": "LACTOSE MONOHYDRATE",
            "code": "EWQ57Q8I5X"
        },
        {
            "name": "CELLULOSE, MICROCRYSTALLINE",
            "code": "OP1R32D61U"
        },
        {
            "name": "SILICON DIOXIDE",
            "code": "ETJ7Z6XBU4"
        },
        {
            "name": "CROSPOVIDONE",
            "code": "2S7830E561"
        },
        {
            "name": "MAGNESIUM STEARATE",
            "code": "70097M6I30"
        },
        {
            "name": "HYPROMELLOSE 2910 (6 MPA.S)",
            "code": "0WZ8WG20P6"
        },
        {
            "name": "TITANIUM DIOXIDE",
            "code": "15FIX9V2JP"
        },
        {
            "name": "POLYETHYLENE GLYCOL 400",
            "code": "B697894SGQ"
        },
        {
            "name": "FERRIC OXIDE YELLOW",
            "code": "EX438O2MRT"
        },
        {
            "name": "POLYSORBATE 80",
            "code": "6OZP39ZG8H"
        },
        {
            "name": "FERRIC OXIDE RED",
            "code": "1K09F3G675"
        },
        {
            "name": "NALTREXONE HYDROCHLORIDE",
            "code": "Z6375YW9SF"
        }
    ],
    "indications": "naltrexone hydrochloride tablets indicated treatment alcohol dependence blockade effects exogenously administered opioids . naltrexone hydrochloride shown provide therapeutic benefit except part appropriate plan management addictions .",
    "contraindications": "reduce risk precipitated withdrawal patients dependent opioids , exacerbation preexisting subclinical withdrawal syndrome , opioid-dependent patients , including treated alcohol dependence , opioid-free ( including tramadol ) starting naltrexone hydrochloride treatment . opioid-free interval minimum 7 10 days recommended patients previously dependent short-acting opioids .",
    "warningsAndPrecautions": "naltrexone hydrochloride tablets , usp available follows : 50 mg : yellow , round , biconvex , film-coated tablets debossed \u201c 326 \u201d one side scored side . ndc : 70518-2718-00 ndc : 70518-2718-01 packaging : 30 1 blister pack packaging : 28 1 blister pack store 20\u00b0 25\u00b0c ( 68\u00b0 77\u00b0f ) ; excursions permitted 15\u00b0 30\u00b0c ( 59\u00b0 86\u00b0f ) [ usp controlled room temperature ] . dispense tight container . repackaged distributed : remedy repack , inc. 625 kolter dr. suite # 4 indiana , pa 1-724-465-8762",
    "adverseReactions": "naltrexone hydrochloride contraindicated : patients receiving opioid analgesics . patients currently dependent opioids , including currently maintained opiate agonists [ e.g . , methadone ) partial agonists ( e.g . , buprenorphine ) . patients acute opioid withdrawal ( ) . individual failed naloxone challenge test positive urine screen opioids . individual history sensitivity naltrexone hydrochloride components product . known cross-sensitivity naloxone phenanthrene containing opioids .",
    "indications_original": "Naltrexone hydrochloride tablets are indicated in the treatment of alcohol dependence and for the blockade of the effects of exogenously administered opioids.\n                  Naltrexone hydrochloride has not been shown to provide any therapeutic benefit except as part of an appropriate plan of management for the addictions.",
    "contraindications_original": "To reduce the risk of precipitated withdrawal in patients dependent on opioids, or exacerbation of a preexisting subclinical withdrawal syndrome, opioid-dependent patients, including those being treated for alcohol dependence, should be opioid-free (including tramadol) before starting naltrexone hydrochloride treatment. An opioid-free interval of a minimum of 7 to 10 days is recommended for patients previously dependent on short-acting opioids.",
    "warningsAndPrecautions_original": "Naltrexone Hydrochloride Tablets, USP are available as follows: 50 mg: Yellow, round, biconvex, film-coated tablets debossed with \u201c326\u201d on one side and scored on other side.\n                  \n                  NDC: 70518-2718-00\n                  NDC: 70518-2718-01\n                  PACKAGING: 30 in 1 BLISTER PACK\n                  PACKAGING: 28 in 1 BLISTER PACK\n                  \n                  Store at 20\u00b0 to 25\u00b0C (68\u00b0 to 77\u00b0F); excursions permitted between 15\u00b0 and 30\u00b0C (59\u00b0 and 86\u00b0F) [see USP Controlled Room Temperature].\n                  Dispense in a tight container.\n                  \n                  Repackaged and Distributed By:\n                  Remedy Repack, Inc.\n                  625 Kolter Dr. Suite #4 Indiana, PA 1-724-465-8762",
    "adverseReactions_original": "Naltrexone hydrochloride is contraindicated in:\n                  \n                     Patients receiving opioid analgesics.\n                     Patients currently dependent on opioids, including those currently maintained on opiate agonists [e.g., methadone) or partial agonists (e.g., buprenorphine).\n                     Patients in acute opioid withdrawal (see\n  \n   WARNINGS).\n \n  \n                     Any individual who has failed the naloxone challenge test or who has a positive urine screen for opioids.\n                     Any individual with a history of sensitivity to naltrexone hydrochloride or any other components of this product. It is not known if there is any cross-sensitivity with naloxone or the phenanthrene containing opioids."
}